Sanofi: Sarclisa Phase 3 Trial Meets Primary Endpoint Of Progression Free Survival

(RTTNews) - Sanofi (SNY) announced the Phase 3 IMROZ trial evaluating the investigational use of Sarclisa or isatuximab in combination with standard-of-care bortezomib, lenalidomide and dexamethasone or VRd met its primary endpoint at a planned interim analysis for efficacy, showing statistically significant improvement in progression-free survival compared with VRd alone in transplant-ineligible patients with newly diagnosed multiple myeloma.

The company said the study results will be submitted for presentation at an upcoming medical meeting and form the basis of a future regulatory submission.

For More Such Health News, visit rttnews.com.